← Back to Search

Radioactive Agent

hematopoietic stem cell infusion for Neuroblastoma

N/A
Waitlist Available
Led By Emily Greengard, MD
Research Sponsored by Masonic Cancer Center, University of Minnesota
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights

Study Summary

This trial is testing a new therapy for neuroblastoma and pheochromocytoma, two cancer types that are difficult to treat. The trial will evaluate how well the therapy works and how safe it is.

Eligible Conditions
  • Neuroblastoma
  • Pheochromocytoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of patients who receive 131 I-MIBG.
Secondary outcome measures
Disease response
Improvement of fatigue
Pain
+3 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: 131 I-MIBG Treatment ArmExperimental Treatment4 Interventions
Therapeutic 131 I-Metaiodobenzylguanidine (131I-MIBG) will be infused intravenously, intravenous fluids will be administered to help maintain urine flow and isotope excretion. Potassium iodide solution will be administered to protect thyroid function. G-CSF will be used if necessary for neutrophil recovery. Hematopoietic stem cell infusion if meets the criteria.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
G-CSF
2014
Completed Phase 4
~1610

Find a Location

Who is running the clinical trial?

Masonic Cancer Center, University of MinnesotaLead Sponsor
271 Previous Clinical Trials
14,525 Total Patients Enrolled
4 Trials studying Neuroblastoma
42 Patients Enrolled for Neuroblastoma
Emily Greengard, MDPrincipal InvestigatorUniversity of Minnesota Department of Pediatrics

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
MIBG for Refractory Neuroblastoma and Pheochromocytoma
2013. "MIBG for Refractory Neuroblastoma and Pheochromocytoma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01850888.
~13 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top